Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Depreciation & Amortization (2020 - 2023)

Historic Accumulated Depreciation & Amortization for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Q3 2023 value amounting to $404000.0.

  • Insight Molecular Diagnostics' Accumulated Depreciation & Amortization rose 332.48% to $404000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $404000.0, marking a year-over-year increase of 332.48%. This contributed to the annual value of $1.5 million for FY2022, which is 8750.0% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Accumulated Depreciation & Amortization of $404000.0 as of Q3 2023, which was up 332.48% from $435000.0 recorded in Q2 2023.
  • In the past 5 years, Insight Molecular Diagnostics' Accumulated Depreciation & Amortization ranged from a high of $1.5 million in Q4 2022 and a low of -$4.2 million during Q3 2020
  • Its 4-year average for Accumulated Depreciation & Amortization is -$64333.3, with a median of $313000.0 in 2020.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Accumulated Depreciation & Amortization skyrocketed by 15559.11% in 2021, and later surged by 332.48% in 2023.
  • Over the past 4 years, Insight Molecular Diagnostics' Accumulated Depreciation & Amortization (Quarter) stood at $313000.0 in 2020, then skyrocketed by 155.59% to $800000.0 in 2021, then soared by 87.5% to $1.5 million in 2022, then crashed by 73.07% to $404000.0 in 2023.
  • Its Accumulated Depreciation & Amortization stands at $404000.0 for Q3 2023, versus $435000.0 for Q2 2023 and $450000.0 for Q1 2023.